Literature DB >> 9751795

All pyruvylated galactose in Schizosaccharomyces pombe N-glycans is present in the terminal disaccharide, 4, 6-O-[(R)-(1-carboxyethylidine)]-Galbeta1,3Galalpha1-.

T R Gemmill1, R B Trimble.   

Abstract

The large N-linked oligosaccharides released from Schizosaccharomyces pombe by endo-beta-N-acetylglucosaminidase H were examined to determine how the negatively chargedpyruvylated galactoses present (Gemmill,T.R., and Trimble,R.B., 1996, J. Biol. Chem ., 271, 25945-25949) were attached to the oligosaccharide chains. Binding of biotinylated human serum amyloid P and peanut agglutinin to native and depyruvylated S.pombe glycoproteins, respectively, indicated that the pyruvylated epitope was likely to be in the beta configuration. Examination by high-field 1H NMR of whole glycans and a disaccharide fragment released from them on partial acid hydrolysis showed that the pyruvylated galactose species was in fact beta1,3-linked to a second galactose, and this occurred an average of five to six times on nominal Gal57Man64GlcNAc N-glycans. The pyruvate-2,(4,6)Gal-beta1,3Gal epitope is chemically similar to acetaldehyde-Galbeta1,3Gal groups found on the glycoproteins from Paramyxovirus-infected bovine kidney cells (Prehm, P., Scheid,A. and Choppin,P.W. ,1979, J. Biol. Chem ., 254, 9669-9677). The 1:1 stoichiometry between pyruvate and beta-linked galactose in these S.pombe glycans indicates that either pyruvate addition to terminal beta1,3Gal is highly efficient or that pyruvylated Gal is transferred en bloc to alpha1,2-linked Gal residues in theN-linked chains. In contradiction to many galactomannan-producing fungi, which add substantial amounts of Gal in the furanose form to their glycoproteins, all detectable Gal in the large S.pombe galactomannans is in the pyranose form, as found in higher eukaryotes. The current work shows that the S.pombe outer chain structure is a poly-alpha1,6Man backbone 2-O-substituted with either Gal or the pyruvylated galactobiose and contains little alpha1,2-linked or 2-O-substituted Man. This is in contrast to the S. cerevisiae outer chain, which is poly-alpha1,6Man substituted with alpha1,2-linked Man sidechains (Ballou,C.E. ,1990, Methods Enzymol , 185, 440-470).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751795     DOI: 10.1093/glycob/8.11.1087

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  6 in total

1.  Glycan Alteration Imparts Cellular Resistance to a Membrane-Lytic Anticancer Peptide.

Authors:  Ken Ishikawa; Scott H Medina; Joel P Schneider; Amar J S Klar
Journal:  Cell Chem Biol       Date:  2017-01-12       Impact factor: 8.116

2.  MADS box transcription factor Mbx2/Pvg4 regulates invasive growth and flocculation by inducing gsf2+ expression in fission yeast.

Authors:  Tomohiko Matsuzawa; Ken-ichi Yoritsune; Kaoru Takegawa
Journal:  Eukaryot Cell       Date:  2011-12-16

3.  Identification of novel α1,3-galactosyltransferase and elimination of α-galactose-containing glycans by disruption of multiple α-galactosyltransferase genes in Schizosaccharomyces pombe.

Authors:  Takao Ohashi; Kazuhito Fujiyama; Kaoru Takegawa
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

4.  Glycoproteins of drusen and drusen-like lesions.

Authors:  Yvonne D'souza; Carolyn J P Jones; Richard Bonshek
Journal:  J Mol Histol       Date:  2007-09-11       Impact factor: 2.611

Review 5.  Pyruvate Substitutions on Glycoconjugates.

Authors:  Fiona F Hager; Leander Sützl; Cordula Stefanović; Markus Blaukopf; Christina Schäffer
Journal:  Int J Mol Sci       Date:  2019-10-05       Impact factor: 6.208

6.  A rationally engineered yeast pyruvyltransferase Pvg1p introduces sialylation-like properties in neo-human-type complex oligosaccharide.

Authors:  Yujiro Higuchi; Sho Yoshinaga; Ken-Ichi Yoritsune; Hiroaki Tateno; Jun Hirabayashi; Shin-Ichi Nakakita; Miho Kanekiyo; Yoshimitsu Kakuta; Kaoru Takegawa
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.